Introduction
The GB virus C (GBV-C) is a non-pathogen member of Flaviviridae family; it is a lymphotropic virus that replicates in human peripheral blood mononuclear cells (PBMC), including B and T lymphocytes. [1] . Several studies show that: (a) GBV-C infection is associated with slower progression and prolonged survival in HIV-infected patients. (b) When GBV-C is added to CD4+ T cells it inhibits HIV entry. (c) Transmission of HIV-1 from mother to child is reduced in mothers co-infected with GBV-C [2] . (d) The RNA + of GBV-C in HIV patients correlates with lower activation of T lymphocytes [3] . These findings have been used to develop new strategies against the spread of HIV. Two GBV-C viral proteins, NS5A and E2, inhibit HIV replication in vitro. NS5A induces the expression of SDF-1 and down regulates CXCR4 in CD4+ T cells. Moreover, NS5A may enhance the resistance of CD4+ T cells to HIV infection [4] . The E2 envelope glycoprotein appears to inhibit the earlier steps of HIV infection, due to an internal fusion peptide that inhibits gp41 fusion to the cell targets [5] . The use of small peptides derived from GBV-C envelope proteins has thus been suggested as a strategy to inhibit HIV-infection [6] [7] [8] .
In an attempt to decrease the rate of HIV infection, a broad range of HIV-1 fusion-entry inhibitors have been explored. Several HIV inhibitors have been reported to block the entry of HIV to target-cells. For example, VIRIP, a derivate from serine protease inhibitor (α-1anti-trypsine) inhibits HIV-1 entry by binding to the fusogenic peptide in gp41 (gp41-FP) and preventing its insertion into the target-cell [9] . Enfuvirtide (T-20), a peptide derived from gp41, blocks conformational changes in gp41 and thus inhibits HIV-1 fusion to cells [10] . E2, a peptide derived from the E2 envelope protein of GBV-C, interacts with the disulphide loop region in gp41of HIV. E2 contains three cysteine residues, which may interfere with the oxidation state of the cysteine in the gp41 disulphide region [11, 12] .
Unfortunately, peptides suffer some limitations such as: low oral bioavailability, short half-life, fast removal and poor ability to cross- physiological barriers. Moreover, hydrophobicity and flexibility can reduce specificity and trigger activation of different receptors or targets, leading to side effects [13] .
HIV is mainly transmitted through infected vaginal and rectal mucosae. Research on the prevention of HIV infection has focused on the development of topical microbicides. However, the first-generation HIV microbicides failed as a result of genital epithelial disruption and inflammation [14] . Damage to the epithelial lining as a result of physical and chemical stress can increase the incidence of HIV, and facilitate penetration of submucosal tissue. Further, the microbiota change in the vaginal mucosa, following prolonged exposure to the high doses of drugs, could lead to a breakdown of the defense barrier in the mucosa and therefore facilitate HIV infection [15] .
The vaginal fluid that covers the mucosa can help the microbicide to reach the epithelium, or remove the microbicide. Unless vaginal microbicides satisfy essential criteria of stability, safety, effectiveness and tolerability, their efficacy and toxicity might be compromised during permeation across mucosal tissue [16] .
A new generation of HIV microbicides is being manufactured with biodegradable carriers such as liposomes, nanoparticles, dendrimers, gels, and films, in order to improves the safety and effectiveness of the drugs [17] [18] [19] . The systems most widely used for this purpose are nanoparticles made with polyesthers such as poly (D, L-lactic-co-glycolic acid) (PLGA). This polymer has been approved by Food and Drug Administration (FDA) and used as colloidal carriers for drug controlled release [20] . It has several advantages such as biocompatibility, biodegradability and non-toxicity [21] . In addition, PLGA shows good reproducibility, controllable release and predictable degradation kinetics [22] . In addition, PLGA properties such as bioadherence and mucoadhesiveness are comparable to the mucoadhesive properties of biopolyaminossacharides such as chitosan. Chitosan, a deacylated product of the linear polysaccharide chitin, has attracted attention as a potential absorption enhancer across mucosal epithelia [23] [24] [25] .
Polymeric nanoparticles (NPs) have been considered as a suitable carrier to entrap proteins and polypeptides, since NPs target specific localization, which offers controllable and site-specific peptide release. In addition, NPs as carriers of anti-HIV peptides have the specific potential to address the main issues of traditional HIV-1 therapy, such as overcoming cellular and anatomical barriers, drug toxicity, drug resistance, suboptimal adherence and virus sequestration [26] . For example, NPs have been used extensively to entrap therapeutic peptides and to improve their activity. In this sense, an analogue of RANTES (PSC-RANTES) encapsulated in polymeric NPs maintained comparable anti-HIV activity with unformulated PSC-RANTES in HeLa cells. Studies ex vivo demonstrated that PSC-RANTES carried by NPs increased tissue uptake and enhanced both tissue permeation and leading localization at the basal layers of the epithelium compared with unformulated PSC-RANTES [27] .
Here we developed PLGA Nanoparticles (NPs) covered with glycolchitosan to encapsulate an HIV fusion inhibitor peptide (E2). Furthermore, we carried out assessments ex vivo and in vivo to examine the ability of NPs to reach the vaginal epithelium. The penetration rate was measured in a swine model using confocal microscopy.
Materials and methods

Materials
Fmoc-protected amino acids, NovaSyn TGA, TGR resins as well as 5(6)-carboxyfluorescein 5(6)-FAM) were purchased from Novabiochem (Merck Millipore, Merck, Darmstad, Germany). Peptide-synthesis-grade dimethylformamide (DMF) and trifluroacetic acid (TFA) were obtained from Scharlau (Barcelona, Spain). Diethyl ether, dichloromethane (DCM) and methanol were obtained from Merck (KGaA, Darmstad, Germany). 2-(1H-7-azabenzotriazole-1-yl)-1. [28] . Couplings were performed by HATU/ DIPEA activation with threefold molar excess of Fmoc-amino acids. The Fmoc was deprotected twice with (20%) piperidine in DMF for 10 min. The stepwise addition of each residue was assessed by Kaiser's test and by the chloranil test for identification of secondary amines (proline residues).
Before the cleavage, the E2 peptidyl-resin was labelled at the Nterminus with 5(6)-carboxyfluorescein, 5(6)-FAM). The carboxylic acid group of the fluorescent dye was activated with N, N'-diisopropylcarbodiimide (DIPCDI) and hydroxybenzotriazole (HOBt). Coupling was carried out with threefold molar excess of the reagents. Fluorescent labeling of the E2 peptidyl-resin was evaluated by Kaiser's test.
The peptide was side chain deprotected and cleaved from resins by a treatment of trifluoroacetic acid TFA, triisopropylsilane (TIS) and water: 9.5%, 2.5%, and 2.5. The reaction was carried out for 3 h at room temperature. The solvents were evaporated in vacuum and the crude peptide was precipitated with cold diethyl ether. Precipitated peptide was dissolved in 30% glacial acetic acid in water and lyophilized.
The peptide was purified by semi preparative HPLC (1260 Infinity, Agilent Technologies, Santa Clara, CA, USA) in an XBridge TM Prep C 8 column (5 μm, 10 × 250 mm, Waters, Milford, MA, USA. E2 was analyzed using a Waters Alliance HPLC with diode array detector with analytical column Kromasyl 100 C18 column (250 mm × 4.6 mm, 5 μm, Teknokroma). The analyses were carried out with linear gradient of 95% water (0.05% TFA)/5% acetonitrile (0.05% TFA). The peptide was purified at 95% by analytical HPLC at 220 nm. E2 and E2-FAM were examined by electrospray ionization mass spectrometry (ESI-MS).
The methods are reported in detail in supplementary materials section.
Preparation of the PLGA NPs loaded E2-FAM (NPsE2-FAM)
The NPs were manufactured by a modified double emulsion method [29] . NPs with E2, E2-FAM and empty NPs were prepared individually. In brief, the NPs were prepared with 50 mg of PLGA dissolved in 1 mL of dichloromethane (organic phase). The preparation was then emulsified under sonication (30 s, 50 W) with a solution containing 1.5 mg of either E2 or E2-FAM, forming a water-in-oil-water emulsion (W 1 /O/ W 2 ). Afterwards, the first emulsion (W 1 /O) was added to 6 mL of previously prepared solution (2.5% PVA and chitosan 0.05%, at pH 4.0) and the mixture was emulsified again by sonication (1 min, 50 W), forming a double emulsion (W 1 /O/W 2 ). The emulsion was stirred overnight to evaporate the solvent and to form and harden the NPs.
NPs were purified by ultracentrifugation for 15 min, 15000 rpm; at 4°C (Beckman Coulter, OPTIMA L-100 K), washed twice and suspended in Milli-Q water.
Physicochemical characterization of the NPsE2
The average particle size (Z av ) and polydispersity index (PI) of both NPsE2-FAM and NPsE2 were determined by photon correlation spectroscopy (PCS) (after 1:10 dilution) with a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) at 25°C using disposable quartz cells and (Malvern Instruments).
NP surface charge, measured as Zeta Potential (ζ), was evaluated using laser-Doppler electrophoresis with M3 PALS system in ZetasizerNano ZS. ζ indirectly indicates the rate of aggregation of particles. A greater ζ (in absolute value) would induce less aggregation due to repulsion forces between the particles. The ζ was calculated applying the Henry equation [30] .
where μ E is the electrophoretic mobility, ε is the dielectric constant of the medium, η is the medium viscosity, Ka is the Deybye-Hückel parameter and f Ka ( ) is a correction factor that considers the thickness of the electrical double layer (1/K ) and particle diameter represented by (a). The unit of K is a reciprocal length. The reported values correspond to the mean ± SD of at least three different batches of each formulation.
Entrapment efficiency (EE%)
The EE percentage of the peptide loaded into the NPs was calculated indirectly by measuring the concentration of the peptide in the dispersion medium. The non-entrapped E2 was separated from the entrapped E2 by ultracentrifugation (at 15000 rpm for 15 min, 4°C). The concentration of the non-entrapped peptide was measured by HPLC UV-VIS. The HPLC system was connected to a Waters ® 515 HPLC Pump (Waters, Milford, MA, USA). The analytical column was a Kromasil 100 C18 (250 mm × 4.6 mm, 5 μm, Teknokroma). The peptide was detected at 280 nm with a flow rate of 1.0 ml/min. The eluents were 95% water (0.05% TFA) and 5% acetonitrile (0.05% TFA) (95:5 v/v). Each sample was diluted with acetonitrile/water (1:10). The EE (%) was determined applying Eq. (2).
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Amino acid analysis
The amino acids composing the peptide entrapped in the NPs were identified and quantified as described by Cohen et al., [31] . In brief, 30 μL of 1-amino-n-butyric acid (2.5 mM) and 1 mL of HCl 12 M were added to 1 mL of the sample (NPsE2 suspension, 166 μg/mL of E2 peptide). Hydrolysis was carried out at 110°C for 16 h. The internal standard (10 mL) was added and diluted with water to 250 mL. The solution was passed through a 0.20 μm filter. Then, the acid was evaporated and dried sample was dissolved with Milli-Q water.
Derivatization was performed by adding 70 μL of borate buffer to 10 μL of filtered hydrolysate sample or standard. The optimal pH range for derivatization is 8.2-9.7, and the solution was briefly vortexed. Then, 20 μL of reconstituted AccQ.Fluor reagent (3 mg/ml in acetonitrile) was added and the mixture was immediately vortexed. The vial was closed and left to stand for one minute at room temperature. It was then placed in a heating block at 50°C, for 10 min.
Chromatographic separation was carried out in a Waters AccQ.Tag amino acid analysis Nova-PakTM column (3.9 mm × 150 mm, 4 μm) fitted with a Nova-PakTM C 18. The column was thermostatted at 37°C and a flow rate of 1.0 mL/min. The injection volume was 20 μL. Mobile phase A consisted of AccQ.Tag eluent A, (100 mL AccQ.Tag A concentrate + 1 L Milli-Q water). Mobile phases B and C were acetonitrile and Milli-Q water, respectively. Reaction of amino acids with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate yielded derivatives that were detected at 254 nm. Qualitative and quantitative analyses were based on retention times and internal standard method, respectively.
In vitro Release studies
The evaluation of the peptide released from NPsE2 were carried out in amber glass Franz type diffusion cells (FDC-400) of 18 mm diameter. A dialysis cellulose membrane MW 12000-14000 Da (Iberoamerica, Spain) was hydrated with the receptor medium (pH 7.4 phosphate buffer 10 mM, DTT 10 mM) for 24 h before use. The membrane was fastened between the donor and the receptor compartments of Franz cells. The donor compartment was filled with 1 mL of NPsE2. The receptor compartment was filled with 5 mL of the receptor medium. The available diffusion area was 0.62 cm 2 . The temperature of the assessment was controlled at 37 ± 1°C to mimic human body temperature. The sink conditions were sustained throughout the experiment for 10 h. Aliquots of 100 μL were withdrawn from the receptor chamber at fixed time intervals and immediately replaced with an equal volume of fresh buffer. The quantification of E2 released was analyzed by HPLC-MS/ MS, using a validated method. The concentration of E2 released was measured as described previously for EE. The data are reported as the mean ± SD of three replicates.
The amount of E2 released was adjusted to the Boltzmann Sigmoidal kinetic model [32] .
where (m) is the mass of each sample expressed in ng. (A 1 ) is the low Y limit, (A 2 ) is the high Y limit, (k) is the slope and (t 0 ) represent the V50. V50 is a modelistic parameter that can determine the time in which half of the maximum peptide is released. A nonlinear least-squares regression was performed using the WinNonLin software (WinNonLin professional edition version 3.3 and Graphpad prism version 6 Demo).
The methods used to detect and quantify E2 (HPLC MS/MS and HPLC UV-VIS), were validated following the ICH guidelines [33] . The HPLC UV-VIS method was validated using acetonitrile/water as the matrix, whilst the receptor medium was used to validate the HPLC MS/ MS method. The parameters studied were: linearity, by determination of slope, intercept, 95% confidence intervals and the regression coefficient (r), limit of detection (LOD) and limit of quantification (LOQ). The precision inter-day was expressed as the mean of the coefficient of variation (CV). Accuracy was defined as the mean of the percentage deviation (EE) for the HPLC UV-VIS method, whilst the accuracy by HPLC MS/MS, was defined as the mean of recovery percentage (RE).
Penetration of the NPsE2 in vaginal mucosa of swine
The penetration was evaluated using NPsE2 and NPsE2-FAM. NPs were carried out for both assessments ex vivo and in vivo. For assessments ex vivo, the vaginal mucosae were obtained from the animal house at Bellvitge (Barcelona University); according to protocol approved by Ethics Committee at the University of Barcelona. The mucosae were maintained in a cryoprotective solution and stored at −80°C until use, following the protocol described by Amores et al. [34] .
2.2.7.1. Evaluation ex vivo of the penetration rate of the NPsE2-FAM and the retained amount of E2. Both the penetration rate and the amount retained were measured using 5 mL Franz cells. The donor compartment contained either NPsE2 or NPsE2-FAM (n = 3), and the receptor compartment was filled with the mix of receptor medium and
Diffusion testing was performed at 300 rpm and 37 ± 1°C. The full thickness mucosa discs were placed between the two cell compartments. The available diffusion area was 0.62 cm 2 . A clamp was used to hold the compartments together. Each assay was performed by triplicate.
To evaluate the penetration rate, at the end of the experiment (5 h), the vaginal tissues were removed and fixed in paraformaldehyde 4% (PFA) for 24 h. Subsequently, the tissues were immersed in sucrose 30% and embedded in the Tissue-Tek ® O.C.T. compound, immersed in liquid nitrogen and stored at -80°C. 25 μm sections perpendicular to the mucosal surface were cut on a cryostat (Leica CM1510, Leica Microsystems) at −20°C. The cell nuclei of the tissues were stained with a solution of DRAQ5 (1:2000). The slides were observed using a confocal laser-scanning microscope (TCS-SL-Leica Microsystems) using λ exc : 488 nm for the visualization of the NPsE2-FAM. The acquired images were processed by the means of IMAGE-J software.
To determine the retained E2 amount, at 5 h intervals, aliquots of 300 μL were withdrawn from the receptor chamber and immediately replaced with an equal volume of receptor medium. At the end of the experiment, tissues were removed and rinsed in PBS and the permeation areas were cut and weighed. The E2 retained in the mucosa was extracted with a mixture of the receptor medium and acetonitrile (80:20, v/v); the solution and the mucosa were mixed for 20 min under cold sonication in an ultrasound bath. The E2 was quantified by HPLC/ MS-MS and expressed as μg/g·cm 2 . The result was the average of three independent experiments.
Evaluation in vivo of the penetration rate of NPsE2-FAM.
Experiments were conducted using four female swine of 25 kg. Before carrying out the experiments, the animals were anesthetized. Aliquots of 1 mL of NPsE2-FAM (0.3 mg/mL) were poured, into the vaginal area. Afterwards, the animals were sacrificed by anesthesia overdose and intact vaginal mucosa was isolated using surgical scissors. Tissues slices were used to evaluate both the NP toxicity and the NPsE2-FAM penetration.
The penetration of NPsE2-FAM was analyzed using a confocal microscope. After the exposure (2 and 5 h), the tissues were fixed by dipping them into PFA (4%) over-night, immersed in sucrose 30% for 5 h, embedded in Tissue-Tek ® O.C.T. compound and immersed in liquid nitrogen. 20 μm sections perpendicular to the mucosa surface were cut on a cryostat (Leica CM1510, Leica Microsystems) at −20°C. The nuclei were stained with DRAQ5. The slides were observed on a confocal laser-scanning microscope, using λ exc : 488 nm for the visualization of NPsE2-FAM. The acquired images were processed by IMAGE-J software.
To evaluate the toxicity of NpsE2-FAM, water was applied to one untreated animal. This was to verify the normal tissue architecture and inflammation status in the vaginal mucosa, following the process mentioned above. Tissues were paraformaldehyde fixed, embedded in paraffin and stained with hematoxylin and eosin. Tissue slices were visually examined for histological features, in a blinded method, using a transmitted-light microscope (Epi-fluorescence microscopy, NIKON). The morphological condition of the vaginal mucosa was examined in 10 different slides.
Statistical analyses
Multiple comparisons were obtained by one-way ANOVA with either Turkey's or a run test, except the histological and confocal studies, which were acquired by using a specific program (Image J). Data are presented as a mean ± SD 3. Results and discussion
Peptide synthesis
E2 is a 20-mer peptide [LCDCPNGPWVWVPAFCQAVG] , with a Mw of 2165, characterized by its high hydrophobic content and the presence of three cysteine residues [11] . These properties enable it to interact with the sequence in the disulphide-loop region in gp41 and to block HIV-1 fusion to the cells. Their specificity and activity was confirmed by comparison with a peptide in which the amino acids were arranged randomly (random peptide). The random peptide showed significantly higher IC 50 values against two different HIV strains than the parent sequence. These findings confirmed that E2 may interfere with the fusion and entry of the HIV-1 to the host cell [12] . In the present study, the peptide and its fluorescent derivative (E2-FAM) were successfully synthesized to a high degree of purity (> 95%) after HPLC semi preparative purification.
Characterization of NPs
The aim of the study was to examine whether NPs could cross the first defense barrier on the surface of the mucosa and reach the epithelium without harming the epithelial lining. Our work also involved preparing PLGA NPs covered with glycol chitosan (GC) to entrap an HIV-1 inhibitor peptide and then release it into the vaginal mucosa of the swine. Chitosan is a natural polysaccharide composed of D-glucosamine and N-acetyl D-glucosamine units. GC is the chitosan conjugated with ethylene glycol, it is water soluble below pH 5.0 and, at the same time, it retains its positive charge at physiological pH values [35] . The properties of the NPs obtained are summarized in Table 1 . The formulation shows an average size (Z av ) of roughly 304 nm, PI values of 0.180; ξ of 30.6 mV ± 4.2 and suitable entrapment efficiency, determined by HPLC UV-VIS validated method (Table 2) . Previous studies have reported that NPs with diameters around 200-500 nm can permeate faster through the vaginal mucus [17] . Therefore, the presence of chitosan may increase the mucoadhesiveness of NPs and the retention time at the administration site, providing them with a positive superficial charge. In addition, chitosan has been associated with the improvement of peptide transport across the epithelial barrier [36] .
Amino acid analysis
Chromatograms corresponding to amino acids from the NPsE2, obtained after acid hydrolysis, are shown in Fig. 1 . The amino acids content of the analyzed NPsE2 suspension are reported in Table 3 . Asparagine and glutamine were deamidated to their respective acids during hydrolysis. They are reported together as Asp/Asn and Glu/Gln. Tryptophan was destroyed during HCl hydrolysis. Proline, glycine and valine were the most abundant amino acids in the sample. The amino Notes: Values are average of three independent batches, and are expressed as mean SD. Abbreviations: Z av , average size; EE, entrapment efficiency; NPs, Nanoparticles; PI, polydispersity index; ξ, Zeta potential and SD, standard deviation.
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acid content in the sample was 0.055 mM (109 μg/mL), which corresponding to 66.65% of total peptide added to NPs. This result is consistent with the results obtained by HPLC UV-VIS method at 280 nm (62.01%). Fig. 2 shows a bi-phasic release profile of E2, characterized by an induction phase (phase I), followed by a sustained phase (phase II). The asymptote was reached at 5 h, maintaining a lag-phase up to 10 h. The release studies were performed for 24 h, but after 10 h, the peptide detection was imprecise. This finding was attributed to peptide aggregation in the medium and adsorptive problems. Thus, DTT was added in the release medium to prevent the aggregation, and the time of the assays was also limited to10 h. During this period, the peptide was easier to detect by HPLC/MS-MS validated method (Table 4) . Although not all the peptide incorporated into NPs was released, the results were fitted to the Boltzmann sigmoidal model. Table 5 shows the model and the corresponding dissolution parameters for statistical analysis of E2 released from NPs.
Release in vitro
A recent study reported that E2 release from liposomes was slower in buffer (PBS) than in a culture medium supplemented with 10% fetal bovine serum DMEM/FBS [28] . Although the release mechanisms of polymer systems are different from those of liposomes, similar results were obtained in the present study: approximately 10% of the peptide encapsulated in NPs was released in the PBS receptor medium. This suggests that the E2 release profile was slowed down, either as a result of a dense polymer with low porosity, or due to peptide-polymer interactions.
Evaluation ex vivo the penetration of NPsE2-FAM and the amount of the E2 retained
To evaluate the transit of the NPs loaded with E2-FAM to the vaginal epithelium, assays with cryopreserved mucosae were conducted ex vivo using the Franz Cells systems. To our knowledge, no study has [98] [99] [100] [101] [102] [103] [104] [105] [106] reported that NPsE2 penetrates vaginal mucosa. However, some authors have described the use of NPs as carriers of antiretroviral drugs. For example, Das Neves and co-workers [17] , reported that polymeric NPs measuring about 200 nm loaded with Dapivirine penetrated the excised vaginal mucosa of swine. In the present study, the NPsE2-FAM of 300 nm also penetrated the vaginal mucosa. The NPsE2-FAM penetration was evaluated by confocal microscopy and the images show a fluorescent signal at the upper-layer of the epithelium attributed to the NPsE2-FAM (Fig.3a) . These observations suggest that the adhesion of the NPsE2-FAM to the epithelium is due to the mucoadhesivity and bioadherence features associated with such systems. Some fluorescent aggregates were also found in the deep zones of the mucosa. The peptide released from NPs and/or NPsE2-FAM may pass through the epithelium by passive diffusion. Lipophilic molecules, such as E2, may cross the epithelial cell layers by the intercellular route or diffusion. The intercellular route may pass through the lipid bilayers or along the narrow aqueous regions associated with polar head groups of the membrane lipids. If so, the peptide would hinder the entry of HIV-1 to the intercellular space, thus preventing fusion of the virus to target cells. Besides assessing the NPsE2-FAM penetration, the amount (Q r ), of E2 retained was also measured, and found to be 26.66 ± 7.23 ng/ g·cm −2 (n = 3), p < 0.05. The E2 permeation flux through the vaginal tissue was not calculated, as it was only detected after 5 h of the experiment. The amount of E2 permeated at 5 h was 2.07 ± 0.65 ng/cm 2 (n = 3), p < 0.05. The amount of E2 permeating through the swine's vagina was lower than that retained in the tissue. This pattern might be repeated within the human mucosa. If the peptide levels in the mucosa were higher than the E2 systemic levels, the chances of blocking the HIV fusion to target-cells would increase and the viral resistance would decrease, which would reduce the adverse effects. The results suggest that diffusion and retention of the NPs/peptide may be influenced by its size and by the pathway through which the peptide crosses the mucosa.
Evaluation in vivo of penetration of the NPsE2-FAM
In contrast to other studies in vivo, in which mice were used to examine the transit of nanoparticles across the vaginal mucosa [37] , our we studied swine vaginal mucosa, which is considered to be similar to human tissue [38] . In addition, both consist of a stratified squamous epithelium supported by connective tissue and of the lamina propria, and they have a similar lipid composition, which is an important aspect of the defense barrier [39] .
The NPsE2-FAM were instilled along vaginal area. At 2 h and 5 h post-treatment the animals were sacrificed by anesthesia overdose and the vaginas were extracted. At 2 h post-treatment, the fluorescent signal was distributed over the surface vaginal epithelial layer (Fig. 3b and c) . This indicates that the NPs migrate across the mucus reaching the epithelium and spreading within the adjacent epithelial layers. However, at 5 h post-treatment, the penetration profile had changed. The fluorescence signal was distributed only in the first epithelial layer (plane cells) with lowest signal intensity. At 5 h, the NPs/Peptide may have diffused through the tissue. If peptide is released, it may penetrate the mucosa through lipid bilayers and interact with cellular membranes, increasing their concentration near the fusion sites within intercellular space. In the absence of the virus, the peptide might be degraded by enzymes present in the mucosa or removed by systemic withdrawal. Furthermore, in all the slides a high concentration of NPs/ peptide was observed inside a certain type of cells, which implies that some cells may take up the NPs/peptide. Future studies will examine this hypothesis.
Toxicity after application of the NPsE2-FAM in vivo
Several methods have been used to explore the safety of anti-HIV microbicides. Many of them are cell-based assays in vitro; these establish the cytotoxic concentration of the drug, CC50, which is the concentration that reduces cell viability by 50%, and the maximum effective concentration, EC50, which is the concentration that gives halfmaximal response. These are essential parameters when developing formulations with suitable doses. However, these assays do not allow us to assess the tissue damage, such as the detachment of the epithelium as a result of drug-induced toxicity or the inflammatory effects of prolonged exposure. Histologic analyses are widely used to evaluate the toxicity after vaginal application of microbicides. The loss of the structure and the presence of inflammatory infiltrates in the lamina propria have been considered an important cytotoxicity issue related to sustained exposure to drugs [40, 41] .
To determine harm, inflammation or epithelial upper-layer detachment, caused by NPsE2 or its degradation products, several slices of mucosa were cut and evaluated by microscopy. The number of epithelial layers in untreated mucosae was compared with the number of epithelial layers in the mucosa treated with NPsE2. In all the slices observed, the number of epithelial layers post-administration was the same as the number of epithelial layers on the untreated mucosa (n = 10). There was no evidence of histopathological abnormality, leukocyte infiltration to the lamina propria or epithelial lesions related to the treatment with NPsE2-FAM. Fig. 4(a-c) shows a conserved mucosa with a multi-layer epithelium followed by connective tissue. This parameter is an indication of the safety of the NPs administered to vaginal mucosa.
Conclusions
We present novel polymeric NPs covered with glycol-chitosan, which were successfully used to incorporate an HIV-1 inhibitor peptide, derived from GB virus C. NPsE2 have interesting physicochemical and morphological features that provide their mobility across the mucus, to reach the vaginal epithelium and release the peptide. Besides, the localization of the NPsE2-FAM at the upper-layers of the epithelial mucosa was considered a key aspect, since the peptide may be released at the site where HIV transmission occurs. Overall data indicate that NPsE2 constitute an interesting approached for the development of putative anti-HIV microbicides.
